In this prospective randomized single-blinded study (reg. ISRCTN11414306), 76 patients with a dysfunctional dialysis fistula or graft due to a single de novo or recurrent stenosis in the access circuit were randomized to receive either conventional PTA (POBA) as a standard of care (n = 38) or PTA + adjunctive PTA with a drug-coated (paclitaxel-resveratrol matrix) SeQuent® Please OTW balloon (n = 38, DCB). Patients were scheduled for follow-up PTA at 3, 6, 9, and 12 months. The time of clinically driven target-lesion reintervention rate (primary patency rate) after the index procedure was analyzed using the log-rank test. The primary patency rates at 12 months after the index procedure were 17% (DCB) vs. 11% (POBA). At 3 months, they were 87% vs. 74%, at 6 months they were 53% vs. 26%, and at 9 months they were 22% vs. 11%. The hazard ratio for DCB was 0.55 (95%CI 0.32 to 0.95). The median time needed for target-lesion reintervention was longer in the DCB group (181 days) than in the conventional PTA group (98 days, p = 0.019). We conclude that PTA with the paclitaxel-resveratrol drug-coated SeQuent® Please OTW balloon in patients with de novo or recurrent stenosis in dialysis arteriovenous fistulas or grafts prolongs the time needed for target lesion reintervention and improves primary patency rates in the first year after the index procedure.

Department of Radiology 1st Faculty of Medicine Charles University 121 08 Prague Czech Republic

Faculty of Health Studies Technical University Liberec 461 17 Liberec Czech Republic

Zobrazit více v PubMed

Lok C.E., Huber T.S., Lee T., Shenoy S., Yevzlin A.S., Abreo K., Allon M., Asif A., Astor B.C., Glickman M.H., et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am. J. Kidney Dis. 2020;75:S1–S164. doi: 10.1053/j.ajkd.2019.12.001. PubMed DOI

Lawson J.H., Niklason L.E., Roy-Chaudhury P. Challenges and novel therapies for vascular access in haemodi-alysis. Nat. Rev. Nephrol. 2020;16:586–602. doi: 10.1038/s41581-020-0333-2. PubMed DOI PMC

Al-Jaishi A.A., Oliver M.J., Thomas S.M., Lok C.E., Zhang J.C., Garg A.X., Kosa S.D., Quinn R.R., Moist L.M. Patency Rates of the Arteriovenous Fistula for Hemodialysis: A Systematic Review and Meta-analysis. Am. J. Kidney Dis. 2014;63:464–478. doi: 10.1053/j.ajkd.2013.08.023. PubMed DOI

Han A., Park T., Kim H.J., Min S., Ha J., Min S.-K. Editor’s Choice—Paclitaxel Coated Balloon Angioplasty vs. Plain Balloon Angioplasty for Haemodialysis Arteriovenous Access Stenosis: A Systematic Review and a Time to Event Meta-Analysis of Randomised Controlled Trials. Eur. J. Vasc. Endovasc. Surg. 2021;62:597–609. doi: 10.1016/j.ejvs.2021.05.043. PubMed DOI

Luo C., Liang M., Liu Y., Zheng D., He Q., Jin J. Paclitaxel coated balloon versus conventional balloon angioplasty in dysfunctional dialysis arteriovenous fistula: A systematic review and meta-analysis of randomized controlled trials. Ren. Fail. 2022;44:155–170. doi: 10.1080/0886022X.2022.2029487. PubMed DOI PMC

Lookstein R.A., Haruguchi H., Ouriel K., Weinberg I., Lei L., Cihlar S., Holden A. Drug-Coated Balloons for Dysfunc-tional Dialysis Arteriovenous Fistulas. N. Engl. J. Med. 2020;383:733–742. doi: 10.1056/NEJMoa1914617. PubMed DOI

Kamann S., Haase T., Stolzenburg N., Löchel M., Peters D., Schnorr J. Resveratrol-Coated Balloon Catheters in Porcine Coronary and Peripheral Arteries. Int. J. Mol. Sci. 2019;20:2285. doi: 10.3390/ijms20092285. PubMed DOI PMC

Speck U., Häckel A., Schellenberger E., Kamann S., Löchel M., Clever Y.P., Peters D., Scheller B., Trog S., Bettink S. Drug Distribution and Basic Pharmacology of Paclitaxel/Resveratrol-Coated Balloon Catheters. Cardiovasc. Interv. Radiol. 2018;41:1599–1610. doi: 10.1007/s00270-018-2018-9. PubMed DOI PMC

Shenoy S., Allon M., Beathard G., Brouwer-Maier D., Dember L.M., Glickman M., Lee C., Litchfield T., Lok C., Huber T., et al. Clinical Trial End Points for Hemodialysis Vascular Access. Clin. J. Am. Soc. Nephrol. 2018;13:490–494. doi: 10.2215/CJN.13321216. PubMed DOI PMC

Tepe G., Gögebakan O., Redlich U., Tautenhahn J., Ricke J., Halloul Z., Meyer D.-R., Waliszewski M., Schnorr B., Zeller T., et al. Angiographic and Clinical Outcomes After Treatment of Femoro-Popliteal Lesions with a Novel Paclitaxel-Matrix-Coated Balloon Catheter. Cardiovasc. Interv. Radiol. 2017;40:1535–1544. doi: 10.1007/s00270-017-1713-2. PubMed DOI

Manns B., Tonelli M., Yilmaz S., Lee H., Laupland K., Klarenbach S., Radkevich V., Murphy B. Establishment and Maintenance of Vascular Access in Incident Hemodialysis Patients: A Prospective Cost Analysis. J. Am. Soc. Nephrol. 2004;16:201–209. doi: 10.1681/ASN.2004050355. PubMed DOI

Ayez N., Fioole B., Aarts R.A., van den Dorpel M.A., Akkersdijk G.P., Dinkelman M.K., de Smet A.A. Secondary interven-tions in patients with autologous arteriovenous fistulas strongly improve patency rates. J. Vasc. Surg. 2011;54:1095–1099. doi: 10.1016/j.jvs.2011.04.023. PubMed DOI

Voorzaat B.M., Janmaat C.J., van der Bogt K.E., Dekker F.W., Rotmans J.I. Patency Outcomes of Arteriovenous Fistulas and Grafts for Hemodialysis Access: A Trade-Off between Nonmaturation and Long-Term Complications. Kidney360. 2020;1:916–924. doi: 10.34067/KID.0000462020. PubMed DOI PMC

MacRae J.M., Dipchand C., Oliver M., Moist L., Lok C., Clark E., Hiremath S., Kappel J., Kiaii M., Luscombe R., et al. Arteriovenous Access Failure, Stenosis, and Thrombosis. Can. J. Kidney Health. Dis. 2016;3:1–11. doi: 10.1177/2054358116669126. PubMed DOI PMC

Zhu Z.-R., Zou L., Xing Y., Tan Y.-C., Xu G.-J., He Z.-J., Cao J.-Q., Wu J.-Y., Liang X.-X., Zhang H.-P., et al. Predictors of primary patency after percutaneous bal-loon angioplasty for stenosis of Brescia-Cimino hemodialysis arteriovenous fistula. Br. J. Radiol. 2020;93:20190505. doi: 10.1259/bjr.20190505. PubMed DOI PMC

Kim W.S., Pyun W.B., Kang B.C. The Primary Patency of Percutaneous Transluminal Angioplasty in Hemodialysis Patients With Vascular Access Failure. Korean Circ. J. 2011;41:512–517. doi: 10.4070/kcj.2011.41.9.512. PubMed DOI PMC

Kavan J., Kudlicka J., Malik J., Chytilova E., Lambert L., Slavikova M., Matras P., Burgetova A. Treatment of failing arterio-venous dialysis graft by angioplasty, stent, and stent graft, Two-years analysis of patency rates and cost-effectiveness. Exp. Ther. Med. 2019;18:4144–4150. doi: 10.3892/etm.2019.8050. PubMed DOI PMC

Kolodgie F.D., Pacheco E., Yahagi K., Mori H., Ladich E., Virmani R. Comparison of Particulate Embolization after Femoral Artery Treatment with IN.PACT Admiral versus Lutonix 035 Paclitaxel-Coated Balloons in Healthy Swine. J. Vasc. Interv. Radiol. 2016;27:1676–1685.e2. doi: 10.1016/j.jvir.2016.06.036. PubMed DOI

Mori M., Sakamoto A., Kawakami R., Sato Y., Jinnouchi H., Kawai K., Cornelissen A., Virmani R., Finn A.V. Paclitaxel- and Sirolimus-coated Balloons in Peripheral Artery Disease Treatment: Current Perspectives and Concerns. Vasc. Endovasc. Rev. 2021;4:e03. doi: 10.15420/ver.2020.16. DOI

Caradu C., Lakhlifi E., Colacchio E.C., Midy D., Bérard X., Poirier M., Ducasse E. Systematic review and updated me-ta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease. J. Vasc. Surg. 2019;70:981–995.e10. doi: 10.1016/j.jvs.2019.01.080. PubMed DOI

Katsanos K., Karnabatidis D., Kitrou P., Spiliopoulos S., Christeas N., Siablis D. Paclitaxel-coated balloon angio-plasty vs. plain balloon dilation for the treatment of failing dialysis access, 6-month interim results from a prospec-tive randomized controlled trial. J. Endovasc. Ther. 2012;19:263–272. doi: 10.1583/11-3690.1. PubMed DOI

Trerotola S.O., Lawson J., Roy-Chaudhury P., Saad T.F. Drug Coated Balloon Angioplasty in Failing AV Fistulas. Clin. J. Am. Soc. Nephrol. 2018;13:1215–1224. doi: 10.2215/CJN.14231217. PubMed DOI PMC

Lazarides M.K., Christaina E., Antoniou G.A., Argyriou C., Trypsianis G., Georgiadis G.S. Plain versus paclitax-el-coated balloon angioplasty in arteriovenous fistula and graft stenosis, An umbrella review. J. Vasc. Access. 2021;23:981–988. doi: 10.1177/11297298211005290. PubMed DOI

Chen X., Liu Y., Wang J., Zhao J., Singh N., Zhang W.W. A systematic review and meta-analysis of the risk of death and patency after application of paclitaxel-coated balloons in the hemodialysis access. J. Vasc. Surg. 2020;72:2186–2196.e3. doi: 10.1016/j.jvs.2020.04.525. PubMed DOI

Dinh K., Limmer A.M., Paravastu S.C.V., Thomas S.D., Bennett M.H., Holden A., Schneider P.A., Varcoe R.L. Mortality After Paclitax-el-Coated Device Use in Dialysis Access, A Systematic Review and Meta-Analysis. J. Endovasc. Ther. 2019;26:600–612. doi: 10.1177/1526602819872154. PubMed DOI

Trerotola S.O., Saad T.F., Roy-Chaudhury P., Lutonix AV Clinical Trial Investigators The Lutonix AV Random-ized Trial of Paclitaxel-Coated Balloons in Arteriovenous Fistula Stenosis, 2-Year Results and Subgroup Analysis. J. Vasc. Interv. Radiol. 2020;31:1.e5–14.e5. doi: 10.1016/j.jvir.2019.08.035. PubMed DOI